ConductScience.org, home

Trial · NCT03806452

Registered outcomes29

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of Patients Achieving at Least a 30% Decrease in ACR Baseline Value6 months
The primary endpoint of this study is the proportion of patients in the hydroxycarbamide and placebo groups achieving at least a 30% decrease in ACR baseline value at 6 months after treatment initiation. Patients who do not achieve at least a 30% decrease of the ACR baseline value at month 6 will be considered non-responders.
SecondaryAbsolute Mean Changes in eGFR Value6 months
SecondaryAbsolute Mean Changes in ACR Value6 months
SecondaryProportion of Patients With a Shift From Macroalbuminuria to Microalbuminuria6 months
SecondaryProportion of Patients With a Shift From Microalbuminuria to Normoalbuminuria6 months
SecondaryProportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria6 months
SecondaryProportion of Patients With a Shift From Microalbuminuria to Macroalbuminuria6 months
SecondaryAbsolute Mean Changes of Systolic Blood Pressure6 months
SecondaryAbsolute Mean Changes of Body Weight6 months
SecondaryAbsolute Mean Changes of Diastolic Blood Pressure6 months
SecondaryAbsolute Mean Changes of Heart Rate Measure6 months
SecondaryAbsolute Mean Changes in White Blood Cells Count6 months
SecondaryAbsolute Mean Changes in Platelets Count6 months
SecondaryAbsolute Mean Changes in Mean Corpuscular Volume6 months
SecondaryAbsolute Mean Changes in Mean Corpuscular Haemoglobin Concentration6 months
SecondaryAbsolute Mean Changes in Mean Corpuscular Haemoglobin6 months
SecondaryAbsolute Mean Changes in Hemoglobin Count6 months
SecondaryAbsolute Mean Changes in Foetal Hemoglobin Count6 months
SecondaryAbsolute Mean Changes in Free Hemoglobin Count6 months and 12 months for responder patients willing to continue the study after month 6.
SecondaryAbsolute Mean Changes in Dense Red Blood Cells Percentage6 months and 12 months for responder patients willing to continue the study after month 6.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03806452/registered